home / stock / nvs / nvs articles
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, fr...
Wall Street Journal Instacart Mulls IPO Price Hike After Arm's Stellar Debut: Targeting $10B Valuation Instacart, the popular grocery-delivery...
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders approved the proposed 100% spin-off of Sandoz. ...
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has entered a development and commercializatio...
In the current market session, Novartis Inc. (NYSE:NVS) share price is at $101.05, after a 0.57% spike. Moreover, over the past month, the stock de...
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. While legal experts acknowledge the lack of a c...
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...